Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 801–900 of 1,000
Available and emerging molecular markers in the clinical management of breast cancer
Giridhar, K. V., & Liu, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1664901 · Cited by 16
Beckman, J. A., Doherty, S. P., Feldman, Z. B., Banks, E. S., Moslehi, J. J., Jaffe, I. Z., Hamburg, N. M., Sheng, Q., & Brown, J. D. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.012 · Cited by 16
Han, Y., Wang, J., Wang, Z., & Xu, B. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100606 · Cited by 17
Aapro, M., Ruíz‐Borrego, M., Hegg, R., Kukiełka-Budny, B., Morales, S. M., Cinieri, S., Freitas‐Júnior, R., García‐Estévez, L., Szombara, E., Borges, G. S., et al. (2019) · The Breast · doi:10.1016/j.breast.2019.01.009 · Cited by 15
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Yang, L., Chen, Y., Wang, N., & Han, W. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-36 · Cited by 16
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020
Sherry, A. D., Hahn, A. W., McCaw, Z. R., Jaoude, J. A., Kouzy, R., Lin, T. A., Minsky, B. D., Fuller, C. D., Meirson, T., Msaouel, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3379 · Cited by 15
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Ke, S., Dang, F., Wang, L., Chen, J.-Y., Naik, M. T., Li, W., Thavamani, A., Kim, N., Naik, N. M., Sui, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47427-w · Cited by 16
Kimmick, G. G., Pilehvari, A., You, W., Bonilla, G., & Anderson, R. T. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07415-6 · Cited by 17
Yang, W.-C., Wei, M., Lee, Y., Huang, C., & Kuo, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102092 · Cited by 16
“Palbociclib, was proved to prolong overall survival (OS) when combined with letrozole for ER-positive, HER2-negative advanced breast cancer [17,18].”
Macy, M. E., Mody, R. J., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Fox, E., Weigel, B. J., Hawkins, D. S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00418 · Cited by 19
Shen, J., Luo, P., & Xu, J. (2024) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241278498 · Cited by 16
Xu, B., Zhang, Q., Luo, Y., Tong, Z., Sun, T., Shan, C., Liu, X., Yao, Y., Zhao, B., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56096-2 · Cited by 20
Investigational drugs for head and neck cancer
Bossi, P., & Alfieri, S. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1175435 · Cited by 16
Publishing interim results of randomised clinical trials in peer-reviewed journals
Counsell, N., Biri, D., Fraczek, J., & Hackshaw, A. K. (2016) · Clinical Trials · doi:10.1177/1740774516664689 · Cited by 15
Hachem, G. E., Gombos, A., & Awada, A. H. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1834385 · Cited by 16
Synthesis and Clinical Development of Palbociclib: An Overview
Konar, D., Maru, S., Kar, S., & Kumar, K. (2020) · Medicinal Chemistry · doi:10.2174/1573406417666201204161243 · Cited by 17
Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic
Kumar, S. S., Freelander, A., & Lim, E. (2021) · Cancers · doi:10.3390/cancers13194972 · Cited by 15
Harbeck, N., Kates, R. E., Schinköthe, T., Schumacher, J., Wuerstlein, R., Degenhardt, T., Lüftner, D., Räth, P., Hoffmann, O., Lorenz, R., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102631 · Cited by 15
Self-citationBlum, J. L., DiCristo, C., Gordon, D., Karuturi, M. S., Oubre, D. N., Jepsen, E., Cuevas, J., Lakhanpal, S., Montelongo, M. Z., Zhang, Z., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07145-1 · Cited by 15
Molecular Biology of Breast Cancer
Aftimos, P. G., Azim, H. A., & Sotiriou, C. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00026-2 · Cited by 16
Other targeted drugs in melanoma.
González‐Cao, M., Rodon, J. A., Karachaliou, N., Sanchez, J. M., Santarpía, M., Viteri, S., Pilotto, S., Teixidó, C., Riso, A. A., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.12 · Cited by 16
Ettl, J. (2016) · Breast Care · doi:10.1159/000447417 · Cited by 15
Novel Targeted Agents and Immunotherapy in Breast Cancer
Mayer, I. A., Dent, R. A., Tan, T. J., Savas, P. S., & Loi, S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175631 · Cited by 15
Self-citationXu, B., Krie, A. K., De, P. K. R., Williams, C. B., Elsey, R. J., Klein, J., & Leyland-Jones, B. R. (2017) · Cureus · doi:10.7759/cureus.1408 · Cited by 15
Goldschmidt, D., Dalal, A. A., Romdhani, H., Kelkar, S. S., Guérin, A., Gauthier, G., Wu, E. Q., Niravath, P. A., & Small, T. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0676-2 · Cited by 16
Current Treatment Options for Breast Cancer Brain Metastases
Raghunath, A., Desai, K. B., & Ahluwalia, M. S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0618-5 · Cited by 15
Overexpression of cyclin‐dependent kinase 4 protein in extramammary Paget's disease
Urata, K., Kajihara, I., Myangat, T. M., Tasaki, Y., Otsuka‐Maeda, S., Sawamura, S., Yamada‐Kanazawa, S., Sakamoto, R., Makino, K., Aoi, J., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14858 · Cited by 16
Pancholi, S., Leal, M. F., Ribas, R., Simigdala, N., Schuster, E. F., Château‐Joubert, S., Zabaglo, L. A., Hills, M., Dodson, A. R., Gao, Q., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1222-0 · Cited by 18
Ribociclib plus fulvestrant in the treatment of breast cancer
Neven, P., Sonke, G. S., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840360 · Cited by 16
Xiang, Y., Liu, C., Chen, L., Li, L., & Huang, Y. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000261 · Cited by 15
A clinical evaluation of treatments that target cell cycle machinery in breast cancer
Fedele, P., Sanna, V., Fancellu, A., & Cinieri, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1672659 · Cited by 16
“Different phase III studies (Paloma2 [38], Monaleesa2 [39], Monaleesa7 [40], Monarch3 [41] explored the first line treatment with palbociclib, ribociclib, abemaciclib plus an aromatase inhibitor or tamoxifen versus endocrine therapy alone in post and premenopausal patients.”
BackgroundNoonan, J., Jarzabek, M. A., Lincoln, F. A., Cavanagh, B., Pariag, A. R., Jurić, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D. I., et al. (2019) · Cancers · doi:10.3390/cancers11122005 · Cited by 15
Spring, L. M., Scarpetti, L., Medford, A. J., Niemierko, A., Comander, A. H., Mulvey, T. M., Schnipper, L. E., Isakoff, S. J., Moy, B., Wander, S. A., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-024-00708-5 · Cited by 17
Cancer-Related Alopecia Risk and Treatment
Kaufman, L. C., Valentic, L., Moulton, H., Rose, L., & Dulmage, B. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01336-2 · Cited by 14
Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
Chen, M., Luo, L., Massoumi, N. L., & Keyomarsi, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2537412 · Cited by 15
Fasching, P. A., Schneeweiß, A., Kolberg, H., Ettl, J., Fehm, T. N., Overkamp, F., & Lüftner, D. (2018) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000510 · Cited by 15
Park, S., Ryu, W., Kim, T. Y., Hwang, Y., Han, H. J., Lee, J. D., Kim, G. M., Sohn, J., Kim, S. K., Kim, M. H., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01210-5 · Cited by 17
Nakamoto, S., Shien, T., Iwamoto, T., Kubo, S., Yamamoto, M., Yamashita, T., Kuwahara, C., & Ikeda, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-60101-x · Cited by 14
Cancer drug related cardiotoxicity during breast cancer treatment
Giordano, G., Spagnuolo, A., Olivieri, N., Corbo, C., Campagna, A., Spagnoletti, I., Pennacchio, R. M., Campidoglio, S., Pancione, M., Palladino, L., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1182493 · Cited by 14
CDK4/6 inhibition in luminal breast cancer
Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0268-2 · Cited by 16
Targeted therapy for breast cancer in older patients
Ponde, N. F., Wildiers, H. P. M. W., Awada, A. H., de Azambuja, E., Deliens, C., & Lago, L. D. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.012 · Cited by 16
Hansra, D. M., Jackson, S., Sequeira, J., Vazirani, R., & Alvarez, R. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1955 · Cited by 15
Babcock, A., Ali, A. A., Balkrishnan, R., Montero, A. J., & Diaby, V. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.7.826 · Cited by 14
Bian, L., Xu, F., & Jiang, Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000923 · Cited by 14
“CDK4/6 inhibitors combined with fulvestrant The treatment of HR-positive advanced breast cancer with CDK4/6 inhibitors combined with fulvestrant was mainly studied in PALOMA-3, MONARCH-2, and MONALEESA-3.”
InfluentialManso, L., Hernándo, C., Galán, M., Oliveira, M., Cabrera, M. A., Bratos, R., Rodriguez, C. A., Ruíz‐Borrego, M., Blanch, S., Llombart‐Cussac, A., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.11.005 · Cited by 14
“Palbociclib, together with the others CDK4/6 inhibitors ribociclib and abemaciclib, received FDA and EMA approval for the treatment of HRþ/HER2- mBC in combination with either AIs or fulvestrant based on the PALOMA-2, MONALEESA 2 and the MONARCH 2 randomized clinical trials, respectively [12,15,17,18].”
BackgroundMethodYuan, Y., Zhang, S., Yan, M., Yin, Y., Song, Y., & Jiang, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-8252 · Cited by 15
Neven, P., Johnston, S. R. D., Toi, M., Sohn, J., Inoue, K., Pivot, X. B., Burdaeva, O. N., Okera, M., Masuda, N., Kaufman, P. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4685 · Cited by 14
Spirin, P., Shyrokova, L., Lebedev, T. D., Vagapova, E. R., Smirnova, P. A., Kantemirov, A. V., Dyshlovoy, S. A., Amsberg, G. V., Zhidkov, M. E., & Prassolov, V. (2021) · Marine Drugs · doi:10.3390/md19090489 · Cited by 14
Microgravity: New aspect for breast cancer treatment, a review
Medha, M., & Roy, A. (2021) · Acta Astronautica · doi:10.1016/j.actaastro.2021.09.045 · Cited by 14
CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
Sang, X., Belmessabih, N., Wang, R., Stephen, P., & Lin, S. (2022) · Cancers · doi:10.3390/cancers14040989 · Cited by 14
Rugo, H. S., Im, S., Joy, A. A., Shparyk, Y. V., Walshe, J. M., Sleckman, B. G., Loi, S., Theall, K. P., Kim, S., Huang, X., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.11.005 · Cited by 16
Self-citationShah, A. N., Santa-Maria, C. A., Mukhija, D., Shah, N. C., Kang, A. K., Kumthekar, P., Burdett, K. B., Chandra, S., Chang, J. C., Tsarwhas, D., et al. (2022) · Clinical Breast Cancer · doi:10.1016/j.clbc.2022.12.006 · Cited by 15
Self-citationMastrantoni, L., Orlandi, A., Palazzo, A., Garufi, G., Fabi, A., Daniele, G., Giannarelli, D., Tortora, G., & Bria, E. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101824 · Cited by 16
Mehata, A. K., Singh, V., Vikas, V., Srivastava, P., Koch, B., Kumar, M., & Muthu, M. S. (2024) · Nanotheranostics · doi:10.7150/ntno.94364 · Cited by 15
PALOMA-3 confirms that CDK4/6 is a key therapeutic target
Errico, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.113 · Cited by 14
The role of fulvestrant in endometrial cancer
Bogliolo, S., Cassani, C., Dominoni, M., Orlandini, A., Ferrero, S., Iacobone, A. D., Viazzo, F., Venturini, P. L., Spinillo, A., & Gardella, B. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1244264 · Cited by 14
Marchetti, P., Maass, N., Gligorov, J., Berger, K., MacDougall, F., Montonen, J., & Lewis, J. (2016) · The Breast · doi:10.1016/j.breast.2016.12.002 · Cited by 14
Vernieri, C., Milano, M., Mennitto, A., Maggi, C., Ferrari, B., Rinaldi, L., Mennitto, R., Stefanetti, C., Re, B., Mariani, G., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4336-z · Cited by 14
The safety and efficacy of palbociclib in the treatment of metastatic breast cancer
Ettl, J., & Harbeck, N. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1347506 · Cited by 16
Self-citationPalbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
Hoste, G., Punie, K., Wildiers, H. P. M. W., Beuselinck, B., Lefever, I., Nieuwenhuysen, E. V., Han, S., Berteloot, P., Concin, N., Salihi, R. R., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4827-6 · Cited by 16
Reinert, T., Coelho, G. P., Mandelli, J., Zimmermann, E., Zaffaroni, F., Bines, J., Barrios, C. H., & Graudenz, M. S. (2019) · Journal of Oncology · doi:10.1155/2019/1947215 · Cited by 14
Pharmacotherapy for Liposarcoma: Current and Emerging Synthetic Treatments
Chamberlain, F., Benson, C., Thway, K., Huang, P. H., Jones, R. L., & Gennatas, S. (2021) · Future Oncology · doi:10.2217/fon-2020-1092 · Cited by 15
Long, Q., Li, X., Wu, G., Zhang, J., & Li, H. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1156 · Cited by 14
Huang, Z., Hu, H., Xian, T., Xu, Z., Tang, D., Wang, B., & Zhang, Y. (2023) · RSC Advances · doi:10.1039/d2ra05932k · Cited by 14
Palbociclib — Taking Breast-Cancer Cells Out of Gear
Carey, L., & Perou, C. M. (2015) · New England Journal of Medicine · doi:10.1056/nejme1506680 · Cited by 14
Recent advances in the medical treatment of breast cancer
Vorobiof, D. (2016) · F1000Research · doi:10.12688/f1000research.9619.1 · Cited by 13
Improving Dissolution Rate and Solubility of Palbociclib Salts/Cocrystal for Anticancer Efficacy
Allu, S., An, J.-H., Park, B. J., & Kim, W. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137756 · Cited by 13
McGrath, M. K., Abolhassani, A., Guy, L., Elshazly, A. M., Barrett, J. T., Mivechi, N. F., Gewirtz, D. A., & Schoenlein, P. V. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1298423 · Cited by 15
“…for advanced ER + breast cancer compared to either antiestrogen used as a single agent treatment, with a doubling of progression-free survival (41, 42); increased median progression-free survival (PFS) of up to 27.6 months for letrozole + palbociclib compared to 14.5 months for letrozole as a…”
BackgroundMethodInfluentialHuang, Y.-Z., Sang, M., Xi, P.-W., Xu, R.-X., Cai, M., Wang, Z.-W., Zhao, J., Li, Y.-H., Yin, P., Wei, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2738 · Cited by 14
Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis
Lamas‐Paz, A., Gutierrez, A. H., Guo, F., Jorquera, G., Morán-Blanco, L., Benedé‐Ubieto, R., Mesquita, M., Estévez‐Vázquez, O., Zheng, K., Mazariegos, M. S., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101230 · Cited by 15
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 14
Beck, J. T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s88037 · Cited by 13
Hertz, D. L., Barlow, W. E., Kidwell, K., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Livingston, R. B., Gralow, J. R., Hayes, D. F., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12904 · Cited by 13
Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
Olson, E. A. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.1.3 · Cited by 14
Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
Tesch, H., Müller, V., Wöckel, A., Ettl, J., Belleville, E., Schütz, F., Hartkopf, A. D., Thill, M., Huober, J., Fasching, P. A., et al. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1270-7481 · Cited by 13
An evaluation of palbociclib as a breast cancer treatment option: a current update
Gallanis, G. T., Pericas, R. I., Riegel, A. T., & Pohlmann, P. R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1838485 · Cited by 14
Barrios, C. H., Freitas‐Júnior, R., Martins, S. J., Bines, J., Estevez-Diz, M. D. P., & Caleffi, M. M. (2021) · JCO Global Oncology · doi:10.1200/go.20.00566 · Cited by 17
Bui, T. B. V., Burgering, B. M. T., Goga, A., Rugo, H. S., & Veer, L. V. ‘. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00473 · Cited by 15
Degenhardt, T., Fasching, P. A., Lüftner, D., Müller, V., Thomssen, C., Schem, C., Witzel, I., Decker, T. W., Tesch, H., Kümmel, S., et al. (2023) · Trials · doi:10.1186/s13063-023-07306-z · Cited by 13
Self-citationJi, D., Luo, Y., Wang, J., Chen, S., Lan, B., Ma, F., Xu, B., & Fan, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11290-7 · Cited by 13
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome
Preston, W. A., Drill, E. N., Boerner, T., Gelfer, R., Harding, J. J., O'Reilly, E. M., Cercek, A., Abou‐Alfa, G. K., Park, W., Balachandran, V. P., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00206 · Cited by 14
Gradishar, W. J. (2016) · Cancer Management and Research · doi:10.2147/cmar.s98249 · Cited by 13
Maurer, C., Ferreira, A. R., Martel, S., Lambertini, M., Ponde, N. F., Aftimos, P. G., de Azambuja, E., & Piccart, M. J. (2018) · The Breast · doi:10.1016/j.breast.2018.02.027 · Cited by 13
Schoos, A., Knab, V. M., Gabriel, C., Tripolt, S., Wagner, D. A., Bauder, B., Url, A., & Fux, D. A. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12514 · Cited by 14
The efficacy of gefitinib supplementation for breast cancer
Ye, J., Tian, T., & Chen, X. (2020) · Medicine · doi:10.1097/md.0000000000022613 · Cited by 13
Huang, W., & Wang, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-52 · Cited by 15
Liu, C., Li, T., Tao, Z., Cao, J., Wang, L., Zhang, J., Wang, B., & Hu, X. (2020) · Medical Science Monitor · doi:10.12659/msm.927187 · Cited by 14
Molenaar‐Kuijsten, L., Braal, C. L., Groenland, S. L., de Vries, N., Rosing, H., Beijnen, J. H., Koolen, S. L. W., Vulink, A. J. E., van Dongen, M. G. J., Mathijssen, R. H. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2455 · Cited by 13
Cardoso, F., Cella, D. F., Velikova, G., Harmer, V., Schumacher-Wulf, E., Rihani, J., Casas, A., & Harbeck, N. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102321 · Cited by 13
Self-citationMcClurg, D. P., Urquhart, G., McGoldrick, T., Chatterji, S., Miedzybrodzka, Z., Speirs, V., & Elsberger, B. (2022) · Cancers · doi:10.3390/cancers14133175 · Cited by 15
Palbociclib - from Bench to Bedside and Beyond
Schmidt, M. (2016) · Breast Care · doi:10.1159/000447001 · Cited by 13
Chalasani, P. (2017) · Oncology · doi:10.1159/000477404 · Cited by 13
Steger, G. G., Domínguez, A., Dobrovolskaya, N., Giotta, F., Tubiana-Mathieu, N., Pecherstorfer, M., Ardizzoia, A., Błasińska-Morawiec, M., Espinosa, E., & Villanova, G. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.05.012 · Cited by 16
Rugo, H. S., Harmer, V., O’Shaughnessy, J., Jhaveri, K. L., Tolaney, S. M., Cardoso, F., Bardia, A., Maheshwari, V. K., Tripathi, S., Haftchenary, S., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152843 · Cited by 13
Noguchi, E., Yamanaka, T., Mukai, H., Yamamoto, N., Chung, C.-F., Lu, Y., Chang, D., Sohn, J., Kim, G. M., Lee, K.-H., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00684-w · Cited by 13
Self-citationTripathy, D., Blum, J. L., Karuturi, M. S., McCune, S. L., Kurian, S., Moezi, M. M., Anderson, D., Gauthier, E. R., Zhang, Z., Montelongo, M. Z., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae291 · Cited by 15
Aslan, M., Aslan, Y., & Levent, A. (2025) · Diamond and Related Materials · doi:10.1016/j.diamond.2025.112001 · Cited by 12
Goel, S., Jovanović, B., Chu, X., Hughes, M. E., Erick, T. K., Russo, D., DiLullo, M. K., Wrabel, E., Jeselsohn, R. M., Lin, N., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2647 · Cited by 13
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 15
O'Sullivan, C. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1201072 · Cited by 13
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.